Humacyte (HUMA) Net Cash Flow (2020 - 2026)

Humacyte (HUMA) has reported Net Cash Flow for 7 consecutive years, with $31.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 226.25% year-over-year to $31.3 million in Q2 2026; TTM through Jun 2026 was -$8.2 million, a 47.6% decrease from a year earlier, with the FY2025 full-year figure at -$44.4 million, down 406.72% from the prior year.
• Net Cash Flow was $31.3 million for Q2 2026 at Humacyte, up from -$2.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $35.1 million in Q1 2024 and troughed at -$68.5 million in Q3 2025.
• A 5-year average of -$7.6 million and a median of -$16.1 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow tumbled 510.36% in 2022 and soared 273.53% in 2024, its largest moves.
• Over 5 years, Net Cash Flow stood at -$13.9 million in 2022, then slumped by 39.92% to -$19.5 million in 2023, then jumped by 225.02% to $24.4 million in 2024, then increased by 27.26% to $31.0 million in 2025, then advanced by 1.03% to $31.3 million in 2026.
• The last three Net Cash Flow figures came in at $31.3 million (Q2 2026), -$2.0 million (Q1 2026), and $31.0 million (Q4 2025), per Business Quant data.